Skip NavigationMarketsBusinessInvestingTechPolitics & PolicyVideoWatchlistInvesting ClubPRO
LivestreamMenuHere are Monday’s biggest calls on Wall Street: Barclays reiterates Eli Lilly as overweight Barclays raised its price target on Eli Lilly to $1,550 per share from $1,400. “Pricing will remain the debate, but the volume opportunity keeps getting bigger. Reiterate OW rating and $1,550 PT.” Canaccord upgrades York Space Systems to buy from hold Canaccord says the stock is too cheap to ignore. ” York Space Systems (YSS) announced Q3/26 results, announcing revenues of $84.2M (down 7.3% y/y) and an Adj. EBITDA loss of ($27.6M).” Jefferies initiates Yarrow Biosciences as buy Jefferies said the biotech company is well positioned. “We view YARW as a compelling pure-play Graves’ disease company…” JPMorgan reiterates Tesla as neutral JPMorgan said it’s getting more constructive on the company’s robotaxi opportunity. “TSLA’s recent rapid ramp of its robotaxi fleet and ride-hailing operations, including this weekend’s launch of customer Cybercab sales, is starting to present early validation of the company’s unique advantage in physical AI, with deep vertical integration across software, manufacturing, and compute.” UBS upgrades Peabody Energy to buy from neutral UBS said it sees a compelling risk/reward. “Peabody Energy is a global coal producer with operations in the US and Australia. Its core segments include: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin and Other US Thermal.” Cantor Fitzgerald initiates Centrus Energy as overweight The firm called the nuclear company “durable.” “We are initiating coverage of Centrus Energy with an Overweight rating and 12-month price target of $130.” UBS reiterates Nvidia as buy UBS lowered its price target to $240 per share from $300 ahead of earnings on Tuesday. “We expect NVDA to beat FQ3 (Oct) revenue by ~$3-4B (e.g. as much as ~$111-112B) and we see FQ4 (Jan) revenue guidance in the ~$130B range (Street ~$125B) and revenue ultimately coming in even higher than this as Rubin remains on track to ramp substantially in FQ4.” Read more. William Blair upgrades Bill.com Holdings to outperform from market perform William Blair said it sees a host of positive catalysts ahead. “We like BILL for longer-term investors seeking exposure to a leading pure-play B2B provider. We see Bill positioned for improving monetization and more robust-than-expected margin expansion.” TD Cowen upgrades SPX Technologies to buy from hold TD Cowen’s said it likes SPX’s growth story. “This was a good story when we initiated and we believe it still is, but the froth has been replaced with AI fear and margins have been reset to reflect higher costs. It’s a more palatable entry for the same attractive growth profile.” Citi reiterates SpaceX as buy Citi raised its price target on SpaceX to $280 per share from $240. “Not only does Flight 15 itself – the successful catch of the Starship using Mechazilla’s arms – represent one of the key milestones we’ve flagged along a multi-year path of upside toward $900+, but we walked away from the event with greater conviction in the outlook for the company’s Super Intelligence segment as well.” UBS upgrades Nucor to buy from neutral UBS said it sees a “cash flow inflection.” “We upgrade NUE to Buy and raise our PT 20% to $307/sh. Despite HRC rising ~$250/st since June, shares are broadly flat, while the import response to a widening arbitrage spread has been slower we expected.” Mizuho upgrades Viking Holdings to outperform from underperform Mizuho said buy the dip. “We are upgrading VIK ahead of 3Q to Outperform from Underperform. Our new target price is $120 (vs prior $82). Shares have lagged materially, underperforming cruise peers (RCL and CCL) over the last 6 months, in large part due to lower river levels in Europe, which we believe to be transitory” Goldman Sachs reiterates CoreWeave as buy Goldman lowered its price target but says it’s sticking with the stock. “We remain Buy rated and adjust our 12-month price target to $101 (from $106) based on 15x EV/EBIT to CoreWeave’s SNTM non-GAAP EBIT.” StoneX upgrades Stagwell to buy from hold StoneX said it likes the company’s revenue mix. “We upgrade STGW shares to Buy from Hold and assign a DCF-based PT of $15, reflecting an exit-EBITDA multiple of 9.4x (GAAP).” Goldman Sachs downgrades Yeti to neutral from buy The firm said it has “less conviction” in the stock. “We downgrade YETI t o Neutral from Buy and lower our 12-month price target to $41 from $57.” Northcoast downgrades Costco to neutral from buy Northcoast downgraded the stock on valuation. “Following the dividend announcement, Costco’s stock made a final push towards, and just above, our $1,100 price target.” RBC upgrades Humana to outperform from sector perform RBC said it sees earnings potential. “We are upgradin g HUM t o Outperform (from SP) to reflect the company’s impressive Stars turnaround, which, alongside disciplined medical cost management amid 23% individual MA membership growth this year, demonstrates significant earnings potential.” Melius upgrades Ingersoll Rand to buy from hold Melius said it sees an accelerating order recovery. “We are upgrading shares of Ingersoll Rand to Buy from Hold.” Gordon Haskett upgrades Texas Roadhouse to buy from hold Gordon Haskett upgraded the stock citing multiple expansion. “We’re upgrading TXRH shares to Buy from Hold and increasing our price target to $220 from $190.”Read More














